Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)
Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)
Lucite deal toy recognizing a joint venture between Ironwood Pharmaceuticals and biotechnology firm COUR. The collaboration will allow Ironwood to develop and commercialize COUR's liver disease therapy CNP-104.(22ALJ081)